10 Most Oversold Penny Stocks to Buy According to Analysts

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Price: $3.59

6-Month Performance: -63.40%

Number of Hedge Fund Holders: 44

Analyst Upside Potential: 457.10%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company focused on developing tumor-infiltrating lymphocyte therapies for solid tumor cancers. On March 1st, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock with a price target of $32.

Pantginis noted that the company exceeded revenue expectations by posting $73.7 million in revenue in Q4 2024, which surpassed the previous year’s results. For the full year, it generated $164.1 million, which was the upper end of its guidance, driven by Amtagvi’s U.S. launch and Proleukin’s growth in the Amtagvi regimen. Moreover, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has reaffirmed its $450 million to $475 million revenue target for 2025, signaling confidence in sustained demand.

The analyst also highlighted that management has plans to scale production to treat 5,000+ patients annually, supporting long-term growth. Moreover, the company has submitted marketing authorization applications in the EU, UK, Canada, and Australia is aimed to diversify revenue streams. It is the most oversold penny stock to buy according to analysts.

While we acknowledge the potential of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.